Pimonidazole

Phase 2Small molecule

UUniversity Health Network, Toronto

Pimonidazole is one of 127 small molecule programs targeting Melanoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

126

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

Pancreatic CancerActive, not recruiting

Prostate CancerActive, not recruiting

HypoxiaActive, not recruiting

MelanomaPreclinical

Active, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

HypoxiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Pimonidazole

UUniversity Health Network, Toronto

Phase 2

2 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Osmitrol

BB. Braun Medical Inc.

Preclinical

—9

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Recruiting

Melanoma

NCT06831071

Q1 2028

PreclinicalActive, not recruiting

Prostate Cancer

NCT02095249

Recruiting

Melanoma

NCT04658303

Q4 2028

N/AActive, not recruiting

Sarcoma

NCT03418818

Clinical

Trials by Indication[1]

Melanoma2 trials

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

Recruiting·YYana Najjar··NCT04658303·20 enrolled

Evaluation of Hypoxia in Primary Melanoma

Recruiting·YYana Najjar··NCT06831071·50 enrolled

Hypoxia2 trials

Hypoxia Analysis in Head and/or Neck Cancer

Unknown status·MMarius Gustav Bredell·Phase 2·NCT02414048·10 enrolled

Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer

Suspended·SSunnybrook Health Sciences Centre·Phase 1/2·NCT03181035·10 enrolled

Prostate Cancer2 trials

Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT01992042·33 enrolled

Hypoxia and Stem Cell Content as Aggression Factors in Prostate Cancer

Active, not recruiting·UUniversity Health Network, Toronto·Preclinical·NCT02095249·39 enrolled

Sarcoma1 trial

FAZA PET/MRI Sarcoma

Active, not recruiting·UUniversity Health Network, Toronto·N/A·NCT03418818·70 enrolled

Pancreatic Cancer1 trial

Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer

Withdrawn·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03718650

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Pimonidazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pimonidazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pimonidazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Health Network, Toronto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity Health Network, Toronto

Pimonidazole

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Q4 2028

Trials by Indication[1]

Melanoma2 trials

Hypoxia2 trials

Prostate Cancer2 trials

Sarcoma1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News